Rockwell Medical Acquires Vantive Hemodialysis Unit for 125 Million Dollars as Seres Posts Strong Trial Data

Rockwell Medical agreed to acquire Vantive's hemodialysis business for 125 million dollars, sending its shares up 14.3 percent in premarket trading on November 3. The deal expands Rockwell's footprint in the renal care market by adding Vantive's established hemodialysis operations to its existing portfolio.

Seres Therapeutics shares rose 9.3 percent in premarket trading after the company reported a 77 percent reduction in bloodstream infections in a clinical trial, a result that signals meaningful progress for its microbiome-based therapeutic program.

Compass Pathways CEO Kabir Nath said the company expects to complete its FDA filing for COMP360, its psilocybin therapy, within two weeks, and is targeting a product launch in the first half of 2027. The filing timeline marks a concrete regulatory milestone for one of the more closely watched psychedelic medicine programs.

Enhanced Group added six new peptides, including BPC-157 and TB-500, to its Live Enhanced telehealth platform on November 3, following an October 28 policy announcement from the U.S. Department of Health and Human Services. The expansion gives clinician-supervised access to peptides that had previously sat in a regulatory gray area.